Clinical cancer vaccine trials

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

1993 • 2,828 citations

Progress in human tumour immunology and immunotherapy

2001 • 1,327 citations

Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

1999 • 1,260 citations

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

1997 • 1,235 citations

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

1999 • 1,131 citations

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

1993 • 986 citations

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

1994 • 934 citations

Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines

1994 • 841 citations

Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

2001 • 828 citations

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1

1999 • 803 citations

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

1994 • 584 citations

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers

2000 • 435 citations

Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses

2000 • 407 citations

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

1999 • 339 citations

Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1997 • 311 citations

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptidesin vivo

1996 • 308 citations

Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.

1994 • 287 citations

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptidesin vivo: Implications for tumor vaccines with melanoma-associated antigens

1996 • 250 citations

Effects of Interleukin-12 on the Immune Response to a Multipeptide Vaccine for Resected Metastatic Melanoma

2001 • 243 citations

Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma

2000 • 232 citations

Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.

1999 • 223 citations

A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by geneMAGE-3

2001 • 222 citations

Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes

1997 • 215 citations

CD4⁺T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production

2001 • 199 citations

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

2001 • 198 citations

Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL

2000 • 172 citations

Oncogenic proteins as tumor antigens

1996 • 157 citations

Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors.

2001 • 152 citations

NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.

2000 • 121 citations

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients

2001 • 114 citations

Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.

2000 • 113 citations

Clonal expansion of melan a-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides

2000 • 110 citations

HLA-peptide tetrameric complexes

1998 • 106 citations

Human papillomarivus vaccines for cervical cancer

1996 • 98 citations

Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide.

2001 • 88 citations

Discrepancy between ELISPOT IFN-γ secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life

2001 • 86 citations

CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences.

2001 • 45 citations

Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells

1994 • 38 citations

Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy

2001 • 35 citations

Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes

2001 • 34 citations

Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen

2001 • 23 citations

Cited By (0)

No citing papers found in database